Anti-Infective Drugs

DRUG4 trials

Sponsors

Beijing Children's Hospital, Wei Zhao, Shandong University

Conditions

Children；InfectionHematological NeoplasmsInfectious Diseases of SpineOsteoarticular Infections

Phase 4

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

RecruitingNCT03844360

Wei ZhaoHematological Neoplasms

Start: 2016-01-31End: 2026-12-31Target: 1500Updated: 2025-03-30

Unknown Phase

Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases

Beijing Children's HospitalChildren；Infection

Start: 2018-07-01End: 2021-12-31Target: 800Updated: 2018-08-23

Model-informed Individualized Treatment of Anti-infective Drugs

RecruitingNCT06711562

Shandong UniversityOsteoarticular Infections

Start: 2024-10-12End: 2026-10-01Target: 300Updated: 2024-12-02

Model-informed Individualized Treatment of Anti-Infective Drugs in Patients With Spinal Infections

RecruitingNCT06711575

Shandong UniversityInfectious Diseases of Spine

Start: 2024-10-12End: 2026-10-01Target: 300Updated: 2024-12-02

Related Papers

Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia

Blood2023-11-02

Improving the efficacy for meropenem therapy requires a high probability of target attainment in critically ill infants and children

Frontiers in Pharmacology2022-10-053 citations

Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia.

2021-07-094 citations

Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.

2020-07-2220 citations